IPO registrations (S-1, F-1) · Registrants
Urovant Sciences Ltd.
- SEC CIK
- 1740547 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2018-07-13, last 2018-09-25; 1 initial registration, 6 amendments
- Outcome
- Final prospectus filed 2018-09-27; declared effective 2018-09-26
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- D0
- Business address
- 5281 CALIFORNIA AVENUE, SUITE 100, Irvine, CA 92617
- EDGAR entity type
- operating
- Insiders and CEO pay
- Urovant Sciences Ltd. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2018-09-25)
- Final price
- $14.00 per share, within the range (424B4 filed 2018-09-27, an initial public offering)
- Shares sold
- 10,000,000
- Gross proceeds
- $140,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol UROV
- Lead underwriters
- J.P. Morgan; Jefferies; Cowen
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Urovant Sciences, Inc. Fuzzy (name and state)
- Business registration: Urovant Sciences, Inc. Fuzzy (name and state)
- Business registration: UROVANT SCIENCES, INC. Fuzzy (name and state)
- Business registration: UROVANT SCIENCES, INC. Fuzzy (name and state)
- Federal award recipient: UROVANT SCIENCES INC. Fuzzy (name and state)
- Lobbying client: UROVANT SCIENCES Fuzzy (name and state)
- SEC filer: Urovant Sciences Ltd. EXACT (CIK (EXACT))
- Person page: Ole Andreas Halvorsen Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Other))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-07-13 | S-1 | S-1 (registration) | Urovant Sciences Ltd. | 0001193125-18-217858 ↗ |
| 2018-07-20 | S-1/A | S-1/A (amendment) | Urovant Sciences Ltd. | 0001193125-18-221855 ↗ |
| 2018-08-15 | S-1/A | S-1/A (amendment) | Urovant Sciences Ltd. | 0001193125-18-249832 ↗ |
| 2018-08-30 | S-1/A | S-1/A (amendment) | Urovant Sciences Ltd. | 0001193125-18-263665 ↗ |
| 2018-09-10 | S-1/A | S-1/A (amendment) | Urovant Sciences Ltd. | 0001193125-18-270163 ↗ |
| 2018-09-17 | S-1/A | S-1/A (amendment) | Urovant Sciences Ltd. | 0001193125-18-274614 ↗ |
| 2018-09-25 | S-1/A | S-1/A (amendment) | Urovant Sciences Ltd. | 0001193125-18-282188 ↗ |
| 2018-09-26 | EFFECT | EFFECT (declared effective) | Urovant Sciences Ltd. | 9999999995-18-002461 ↗ |
| 2018-09-27 | 424B4 | 424B4 (final prospectus) | Urovant Sciences Ltd. | 0001193125-18-285778 ↗ |
| 2019-11-26 | EFFECT | EFFECT (declared effective) | Urovant Sciences Ltd. | 9999999995-19-002675 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-09-25 | S-1/A | registration statement | $14.00–$16.00 | 10,000,000 | - | Nasdaq UROV | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2018-09-27 | 424B4 | final prospectus | $14.00 | 10,000,000 | $140,000,000 | Nasdaq UROV | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Dexcel Pharma Technologies Ltd. | Other; TenPercentOwner | 13 | 2018–2019 | ||
| Dexxon Holdings Ltd. | Other; TenPercentOwner | 13 | 2018–2019 | ||
| Ebersole Nori | Officer | SVP&CHRO-Urovant Sciences,Inc.; SVP;CHRO/Urovant Sciences, Inc | 3 | 2018–2019 | |
| Haag-Molkenteller Cornelia | Officer | CMO of Urovant Sciences, Inc.; CMO/Urovant Sciences, Inc. | 7 | 2018–2021 | |
| HALVORSEN OLE ANDREAS | Other; TenPercentOwner | 20 | 2018–2019 | person page Fuzzy | |
| Katkin Keith | Director,Officer | PEO;CEO-Urovant Sciences,Inc.; PEO;CEO/Urovant Sciences, Inc. | 8 | 2018–2020 | |
| Kurstjens Sef | Director | 6 | 2018–2021 | ||
| Legault Pierre | Director | 6 | 2018–2021 | ||
| Lo Andrew | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Machado Patrick | Other; TenPercentOwner | 11 | 2018–2019 | ||
| McFadden Michael E. | Officer | CCO of Urovant Sciences, Inc.; CCO/Urovant Sciences, Inc. | 3 | 2018–2019 | |
| OCAMPO CHRISTINE | Officer | PAO; CAO/Urovant Sciences,Inc.; PAO;CAO/Urovant Sciences, Inc; PFAO;CAO/Urovant Sciences, Inc; PFAO;CAO/Urovant Sciences,Inc. | 6 | 2018–2021 | |
| Oren Dan | Other; TenPercentOwner | 13 | 2018–2019 | ||
| Ott David C. | Other; TenPercentOwner | 20 | 2018–2019 | ||
| POTTER MYRTLE S | Director | 6 | 2018–2021 | ||
| QVT Associates GP LLC | TenPercentOwner | 11 | 2018–2019 | ||
| QVT Fund V LP | TenPercentOwner | 2 | 2018 | ||
| Roivant Sciences Ltd. | TenPercentOwner | 11 | 2018–2019 | ||
| Shabet Rose Sharon | Other; TenPercentOwner | 20 | 2018–2019 | ||
| Smith Bryan E. | Officer | GC of Urovant Sciences,Inc.; GC/Urovant Sciences, Inc. | 8 | 2018–2021 | |
| SoftBank Vision Fund L.P. | Other; TenPercentOwner | 11 | 2018–2019 | ||
| SVF GP (Jersey) Ltd | Other; TenPercentOwner | 11 | 2018–2019 | ||
| SVF Holdings (UK) LLP | Other; TenPercentOwner | 11 | 2018–2019 | ||
| SVF Investments (UK) Ltd | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Torti Frank | Director | 3 | 2018–2019 | ||
| VGE III Portfolio Ltd. | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Viking Global Equities II LP | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Viking Global Equities LP | TenPercentOwner; TenPercentOwnerOther | 11 | 2018–2019 | ||
| VIKING GLOBAL INVESTORS LP | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Viking Global Opportunities GP LLC | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Viking Global Opportunities Portfolio GP LLC | Other; TenPercentOwner | 11 | 2018–2019 | ||
| VIKING GLOBAL PERFORMANCE LLC | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Viking Long Fund GP LLC | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Viking Long Fund Master Ltd. | Other; TenPercentOwner | 11 | 2018–2019 | ||
| Viking Global Equities Master Ltd. | Other; TenPercentOwner | 10 | 2019 | ||
| Robinson James A. Jr. | Director; Director,Officer | PEO; CEO/Urovant Sciences, Inc; PEO;CEO/Urovant Sciences, Inc. | 7 | 2019–2021 | |
| QVT Financial Investment Cayman Ltd. | TenPercentOwner | 9 | 2019 | ||
| BANSAL AJAY | Officer | PFO;CFO/Urovant Sciences, Inc.; See Remarks | 4 | 2019–2021 | |
| Dainippon Sumitomo Pharma Co Ltd | Other; TenPercentOwner | 2 | 2020 | ||
| Sumitomo Chemical Co., Ltd. | Other; TenPercentOwner | 2 | 2020 | ||
| Sumitovant Biopharma Ltd. | TenPercentOwner | 2 | 2020 | ||
| Nishinaka Shigeyuki | Director | 1 | 2020 | ||
| Hindman James M. | Director | 4 | 2020–2021 | ||
| Johnston Walt | Officer | See Remarks; SVP, Commercial, USI | 3 | 2020–2021 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Urovant Sciences, Inc. | CA | State business registries | name and state |
| Business registration | Urovant Sciences, Inc. | CA | State business registries | name and state |
| Business registration | UROVANT SCIENCES, INC. | CA | State business registries | name and state |
| Business registration | UROVANT SCIENCES, INC. | CA | State business registries | name and state |
| Federal award recipient | UROVANT SCIENCES INC. | CA | Federal spending (USAspending) | name and state |
| Lobbying client | UROVANT SCIENCES | CA | Federal lobbying (LDA) | name and state |
| Paying company | UROVANT SCIENCES INC | CA | Open Payments (drug and device company payments) | name and state |
| SEC filer | Urovant Sciences Ltd. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Ole Andreas Halvorsen | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Other) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.